CD8A and neoplasm: For example, Gal-3 inhibition plus anti-OX40 therapy reduces monocytic myeloid suppressor cell (M-MDSC)-meditated immune suppression thereby increasing CD8+ T cell recruitment leading to increased tumor regression (37).